Nanbu Wang

Dr. Nanbu Wang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
NWNanbu Wang
Nanbu Wang
QZQinxin Zhang
Qinxin Zhang
LLLaiyu Luo
Laiyu Luo
BNBaile Ning
Baile Ning
YFYongqi Fang
Yongqi Fang

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
NWNanbu Wang
Nanbu Wang
HWHaoyu Wang
Haoyu Wang
QPQi Pan
Qi Pan
JKJian Kang
Jian Kang
ZLZiwen Liang
Ziwen Liang
RZRonghua Zhang
Ronghua Zhang
β‐Asarone is the main constituent of Acorus tatarinowii Schott and exhibits important effects in diseases such as neurodegenerative and neurovascular diseases. Icariin (ICA) is a major active ingredient of Epimedium that has attracted increasing attention because of its unique pharmacological effects in degenerative disease. In this paper, we primarily explored the effects of the combination of β‐asarone and ICA in clearing noxious proteins and reversing cognitive deficits. The accumulation of damaged mitochondria and mitophagy are hallmarks of aging and age‐related neurodegeneration, including Alzheimer’s disease (AD). Here, we provide evidence that autophagy/mitophagy is impaired in the hippocampus of APP/PS1 mice and in Aβ1‐42‐induced PC12 cell models. Enhanced mitophagic activity has been reported to promote Aβ and tau clearance in in vitro and in vivo models. Meanwhile, there is growing evidence that treatment of AD should be preceded by intervention before the formation of pathological products. The efficacy of the combination therapy was better than that of the individual therapies applied separately. Then, we found that the combination therapy also inhibited cell and mitochondrial damage by inducing autophagy/mitophagy. These findings suggest that impaired removal of defective mitochondria is a pivotal event in AD pathogenesis, and that combination treatment with mitophagy inducers represents a potential strategy for therapeutic intervention.

14 January 2025 in Archives of Gerontology and Geriatrics
Verified
Journal Article
Open access
QSQuan Sun
Quan Sun
YWYulong Wei
Yulong Wei
HXHongting Xie
Hongting Xie
JLJiaxuan Lyu
Jiaxuan Lyu
JZJingpei Zhou
Jingpei Zhou
NWNanbu Wang
Nanbu Wang
Late-life depression (LLD) represents a growing global public health concern. This study aimed to assess the worldwide burden of LLD using comprehensive data. Leveraging the latest evidence from the Global Burden of Disease Study, we analyzed trends in LLD burden from 1990 to 2021, encompassing incidence, prevalence, and disability-adjusted life years (DALYs). We quantified disparities in LLD burden across socioeconomic, gender, regional, and national dimensions. Decomposition analysis was employed to identify key drivers of LLD burden variation. Frontier analysis illustrated the potential for burden reduction in various countries. Globally, there were 49,137,544 new cases, 46,672,175 prevalent cases, and 7,351,377 DALYs attributed to LLD in 2021. Between 1990 and 2021, the agestandardised incidence rate (ASIR), age-standardised prevalence rate (ASPR), and age-standardised DALYs rate (ASDR) of LLD all rose. In 2021, low SDI regions exhibited the highest all ASRs, while middle SDI regions had the fastest growth rates in these indicators. Regionally, Central and Eastern Sub-Saharan Africa had the highest ASIR, ASPR, and ASDR, respectively. Nationally, Uganda ranked highest in all ASRs in 2021. Women had higher burdens than men. Population growth was a primary driver of DALYs increase in middle SDI regions that had the greatest potential for improvement. The global burden of LLD has risen, with marked inequities across SDI, gender, region, and country. The burden is most pronounced in low and middle SDI regions. These findings offer guidance for developing LLD screening guidelines and enhancing prevention and intervention strategies in relevant countries, particularly Uganda.

4 February 2024 in Behavioural Brain Research
Verified
Journal Article
Closed access
ZWZhifang Wang
Zhifang Wang
JZJingpei Zhou
Jingpei Zhou
BZBin Zhang
Bin Zhang
ZXZhanqiong Xu
Zhanqiong Xu
HWHaoyu Wang
Haoyu Wang
NWNanbu Wang
Nanbu Wang

22 July 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
XLXinyu Li
Xinyu Li
JZJingpei Zhou
Jingpei Zhou
WPWanqing Peng
Wanqing Peng
RZRenhui Zhao
Renhui Zhao
QSQuan Sun
Quan Sun
NWNanbu Wang
Nanbu Wang
Backgrounds: Early-onset Parkinson’s disease (EOPD) presents a significant financial burden on healthcare systems and medical expenses. However, there has been a lack of comprehensive quantitative assessments to fully understand the extent of this burden. The Global Burden of Diseases (GBD) initiative aims to provide a standardized and thorough evaluation of these factors on a global, regional, and national scale. This study aimed to calculate the global burden of EOPD and characterize regional disparities, SDI-based inequalities, and gender differences in disease burden, with a focus on trends from 1990 to 2021.Methods: We utilized data from the GBD Study 2021 to analyze the burden of EOPD by examining factors such as incidence, prevalence, disability-adjusted life years (DALYs), and mortality rates. We focused on trends in EOPD incidence, prevalence, DALYs, and deaths from 1990 to 2021. Additionally, socio-demographic index (SDI)-related determinants that influence EOPD DALYs and characterized the disparities in EOPD burden associated with different SDI levels over the same period.Results: In EOPD, a significant increase in age-standardized rates for incidence, prevalence, and DALYs while the death rate declined. Males exhibited a higher burden than females across all metrics. Geographic disparities showed that East Asia had the highest rates of incidence and DALYs, while Andean Latin America recorded the highest prevalence. Countries with higher SDI levels, particularly China, Bolivia, and Peru, bore the greatest burden. Socioeconomic patterns suggested high-middle SDI regions experienced the highest rates of incidence and prevalence, whereas middle-SDI regions showed the highest rates of disability and mortality. Decomposition analysis revealed population growth was the primary driver of increased DALYs in middle-SDI regions. Additionally, inequality analysis indicated that countries with higher SDI levels faced a disproportionately lower burden of disease.Conclusion: This study confirms a global increase in the burden of EOPD, and indicate rising incidence and prevalence rates, an increase in DALYs, and a decline in mortality rates. A notable predominance of male cases, along with significant geographic and socioeconomic disparities. Regions with a middle SDI experience the most significant burden of disability and mortality, primarily driven by population growth. This underscores the urgent need for targeted interventions to address these inequities.

1 October 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
QSQuan Sun
Quan Sun
HXHongting Xie
Hongting Xie
LHLongchao Hao
Longchao Hao
JDJiayi Ding
Jiayi Ding
JHJiaming Hong
Jiaming Hong
NWNanbu Wang
Nanbu Wang
Purpose: Migraine is the most disabling neurological disorder in children and adolescents. This study aimed to comprehensively assess the global burden of migraine in children and adolescents. Methods: Utilizing the latest data from the Global Burden of Disease (GBD) 2021, trends and disparities in incidence, prevalence, and disability-adjusted life years (DALYs) for migraine among children and adolescents were quantified by sex, age, socio-demographic index (SDI), region, and country. Decomposition analysis and frontier analyses were applied to investigate the underlying factors for changes in burden and the potential for future improvements, respectively. Results: In 2021, there were 36,794,858 new cases, 205,729,235 prevalent cases, and 7,515,775 DALYs caused by migraine in children and adolescents. From 1990 to 2021, age-standardised incidence rates (ASIR), age-standardised prevalence rates (ASPR), and age-standardised rates of DALYs (ASDR) for migraine in children and adolescents have risen, particularly among males, adolescents aged 15– 19 years, regions with middle and higher SDI, East Asia, and Norway. Overall, the burden was higher in females than in males. In 2021, adolescents aged 10– 14 exhibited the highest ASIR, whereas adolescents aged 15– 19 had the highest ASPR and ASDR. The highest ASPR and ASDR were in low-middle SDI regions, while the highest ASIR was in high SDI regions. Tropical Latin America and Brazil had the highest ASRs regionally and nationally, respectively. Population growth and epidemiological changes drove the increase in DALYs. Regions with middle and higher SDIs hold the greatest improvement potential. Conclusion: The global burden of migraine in children and adolescents has increased substantially, disproportionately affecting females, adolescents aged 15– 19 years, and low-middle SDI regions, while the greatest potential for improvement lies in middle and higher SDI regions, especially Brazil. These findings underscore the need for targeted public health policies and interventions tailored to pediatric migraine across diverse settings.